Revance Therapeutics Company Profile (NASDAQ:RVNC)

Analyst Ratings

Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $43.80 (223.01% upside)

Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
Show:
DateFirmActionRatingPrice TargetActions
6/23/2016Brean CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016SunTrust Banks Inc.Lower Price TargetBuy$46.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Piper Jaffray Cos.Reiterated RatingOverweight$54.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016GuggenheimReiterated RatingBuy$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015William BlairReiterated RatingBuy$59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2015BMO Capital MarketsReiterated RatingOutperform$24.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Revance Therapeutics (NASDAQ:RVNC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.83)($0.71)$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2016Q415($0.86)($0.83)$0.09 million$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($1.01)($0.81)$0.10 million$0.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q415($0.84)($0.71)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.69)($0.65)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/2/2015($0.53)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.69)($0.60)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.68)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q1 14($0.87)($1.93)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.07)($0.66)($0.87)
Q2 20162($0.91)($0.91)($0.91)
Q3 20162($0.95)($0.93)($0.94)
Q4 20162($1.02)($0.95)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Revance Therapeutics (NASDAQ:RVNC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Curtis RueggEVPSell1,000$18.25$18,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2016Curtis RueggEVPSell1,000$16.18$16,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Curtis RueggEVPSell1,000$19.11$19,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2016Curtis RueggEVPSell1,000$20.43$20,430.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/8/2016Curtis RueggEVPSell1,000$18.14$18,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Curtis RueggEVPSell2,000$33.06$66,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Arthur Peter BertolinoEVPSell7,753$39.11$303,219.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Curtis RueggEVPSell3,000$30.33$90,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Curtis RueggEVPSell3,000$31.03$93,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Curtis RueggEVPSell3,000$33.53$100,590.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Curtis RueggEVPSell3,000$26.42$79,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Curtis RueggEVPSell2,000$22.23$44,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Curtis RueggEVPSell1,500$18.61$27,915.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Curtis RueggEVPSell500$18.00$9,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Curtis RueggEVPSell1,000$16.80$16,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Curtis RueggEVPSell1,000$17.25$17,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Curtis RueggEVPSell1,000$16.45$16,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2014L Daniel BrowneCEOBuy6,000$16.67$100,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Curtis RueggEVPSell1,000$16.00$16,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Curtis RueggEVPSell2,000$20.55$41,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Jacob WaughInsiderSell97,713$20.73$2,025,590.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
DateHeadline
07/22/16 09:11 AMSHAREHOLDER ALERT: SARRAF GENTILE LLP INVESTIGATING REVANCE THERAPEUTICS, INC.
07/21/16 06:35 PMEarnings Focus and Crowd Sourced Sentiment Review for Revance Therapeutics, Inc. (NASDAQ:RVNC) - TGP
07/21/16 06:35 PMAre Analysts Bullish Revance Therapeutics Inc (NASDAQ:RVNC) After Last Week? - Consumer Eagle
07/21/16 06:35 PMRevance Therapeutics Inc. (RVNC) Drops 6.81% on July 19 - Equities.com
07/21/16 06:35 PMRevance Therapeutics Inc (NASDAQ:RVNC) Stock Technicals at Critical Inflection Point - CML News
07/21/16 03:05 PMRevance Therapeutics to Release Second Quarter 2016 Financial Results Thursday, August 4, 2016 - [Business Wire] - Revance Therapeutics, Inc. , a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will release second quarter 2016 financial results on Thursday, August 4, 2016 after the close of market.
07/20/16 09:06 AMIs Selling Revance Therapeutics Inc Here a Winning Strategy? - Consumer Eagle
07/20/16 09:06 AMRevance Therapeutics, Inc. (NASDAQ:RVNC): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 11:48 AMTrading Performance and Target Watch for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph
07/15/16 01:38 PMThese 5 Stocks Are Primed for Breakouts -
07/15/16 11:28 AMRevance Therapeutics (RVNC) Completes Pre-Phase 3 Meeting with FDA for RT002 Injectable - StreetInsider.com
07/14/16 06:29 PMCrowd Rating and Earnings Recap for Revance Therapeutics, Inc. (NASDAQ:RVNC) - Telanagana Press
07/14/16 06:29 PMEye on Stock Volatility for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Engelwood Daily
07/14/16 03:03 PM4:03 pm Revance Therapeutics announces it is moving forward with an IND submission for phase 3 clinical program for RT002 & other supportive studies required for the BLA filing after its pre-phase meeting with the FDA -
07/14/16 03:02 PMRevance Announces Completion of Pre-Phase 3 Meeting with FDA for RT002 Injectable to Treat Glabellar Lines - [Business Wire] - Revance Therapeutics, Inc. , a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of its Type B / pre-IND / pre-Phase 3 meeting with the U.S.
07/13/16 09:06 AMHow Analysts Feel About Revance Therapeutics Inc (NASDAQ:RVNC)? - Press Telegraph
07/09/16 09:19 AMRevance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Engelwood Daily
07/07/16 09:00 AMNASDAQ:RVNC Stockholder Notice: Investigation of potential Wrongdoing at Revance Therapeutics Inc
07/06/16 06:35 PMStock Moving in on a Recent Low: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph
07/06/16 06:35 PMRevance Therapeutics Inc. (RVNC) Drops 5.21% on July 05 - Equities.com
07/05/16 05:56 PMHow Analysts Rated Revance Therapeutics Inc (NASDAQ:RVNC) Last Week? - Press Telegraph
07/05/16 03:19 PMREVANCE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex -
07/05/16 07:00 AMRevance Appoints Industry Leader Julian S. Gangolli to its Board of Directors - [Business Wire] - Revance Therapeutics, Inc. , a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S.
07/04/16 05:23 PMShare Performance Recap for: Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph
07/02/16 05:47 PMRevance Therapeutics Incorporated (NASDAQ:RVNC) Sellers Increased By 11.1% Their Shorts - Press Telegraph
06/29/16 08:58 AMEquity Research and Technical Review on Revance Therapeutics, Inc. (NASDAQ:RVNC) - Press Telegraph
06/29/16 08:58 AMRevance Therapeutics Inc (RVNC) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 06:53 PMRevance Therapeutics, Inc. (NasdaqGM:RVNC) Stock Momentum Hits Weakness - CML News
06/23/16 06:53 PMBrokers Issue Average Price Target Of 42.33 On Revance Therapeutics Inc (RVNC) - Fiscal Standard
06/21/16 10:32 AMInvestigation for Investors in Shares of Revance Therapeutics Inc (NASDAQ:RVNC) Announced
06/20/16 05:55 PMRevance Therapeutics Inc (RVNC) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 05:58 PMRevance Therapeutics Inc. (RVNC) is Trading Higher on Unusual Volume for June 15 - Equities.com
06/15/16 06:08 PMPerformance report of the company: Revance Therapeutics, Inc. (NASDAQ:RVNC) - News Oracle
06/15/16 06:08 PMRevance Therapeutics Inc. (RVNC) Sank To A New Low On Study Results - RTT News
06/15/16 06:08 PMRevance Therapeutics Inc. (RVNC) Jumps 7.19% on June 15 - Equities.com
06/15/16 10:45 AMTrending Stocks Update: Navistar International Corporation (NYSE:NAV), Revance Therapeutics, Inc. (NASDAQ:RVNC) - Beacon Chronicle
06/15/16 10:45 AMAnalyst Downgrades: Baidu Inc (ADR), Revance Therapeutics Inc, and Chesapeake Energy Corporation - Schaeffers Research (blog)
06/15/16 10:45 AMSummary of Analyst's Study: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Revance Therapeutics, Inc ... - Street Updates
06/14/16 05:57 PMRevance Therapeutics Drops on Missed Late Stage Results
06/14/16 05:57 PMRevance Therapeutics Inc (NASDAQ:RVNC) Might Be Oversold On Its Latest Discontinuation
06/14/16 10:59 AMMoonlight Vista Sees Potential In Wowo (JMU); Revance Therapeutics (RVNC) Slips Into Negative Zone
06/14/16 10:59 AMRevance Therapeutics Inc. (RVNC) Is Down After Phase 3 Study Failed
06/14/16 10:59 AMRevance Therapeutics (RVNC) Announces RT001 REALISE 1 Phase 3 Missed co-Primary, Other Endpoints
06/14/16 10:59 AMRevance's Lead Candidate Fails in Phase III Crow's Feet Study
06/14/16 10:59 AMAnalyst Downgrades: Baidu Inc (ADR), Revance Therapeutics Inc, and Chesapeake Energy Corporation
06/14/16 10:59 AMRevance Therapeutics Inc. (RVNC) Is Sinking On Disappointing Study Results
06/14/16 10:48 AMWhy is Revance Therapeutics (RVNC) Stock Plummeting Today? -
06/14/16 10:45 AMWhy Revance Therapeutics Is Crashing 23% Today -
06/14/16 10:20 AMRevance Therapeutics (RVNC) Stock Plunging on Drug Results -
06/14/16 09:05 AMBrean Downgrades Revance Therapeutics Following RT-001 Fail - Brean Capital's Difei Yang downgraded Revance Therapeutics Inc (NASDAQ: RVNC) from Buy to Hold and removed the price target. The downgrade came after RT-001 failed a Phase III study for Crow's Feet. Related Link: Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out Besides RT-001's failure, Yang needed "more clarity on the Phase ...Full story available on Benzinga.com

Social

About Revance Therapeutics

Revance Therapeutics logoRevance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RVNC
  • CUSIP:
Key Metrics:
  • Previous Close: $13.57
  • 50 Day Moving Average: $14.69
  • 200 Day Moving Average: $18.29
  • P/E Ratio: N/A
  • P/E Growth: -0.33
  • Market Cap: $386.00M
  • Beta: 1.4
  • Current Year EPS Consensus Estimate: $-3.49 EPS
  • Next Year EPS Consensus Estimate: $-3.09 EPS
Additional Links:
Revance Therapeutics (NASDAQ:RVNC) Chart for Saturday, July, 23, 2016